Tired Of Fighting For Resources? Set Up Your Own Foundation

Six years ago, neurologist J. William Langston stumbled onto an exciting discovery, a contaminated synthetic heroin that seemed to trigger symptoms of Parkinson's disease. Almost overnight, Langston was thrust into the limelight. Reporters flocked to his office. Foundations invited him to apply for grants. His lab began reporting steady progress in the long struggle toward a cure for Parkinson's, a degenerative disease that affects half a million people in the United States. But success brought

Written byGlennda Chui
| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

But success brought problems as well as accolades. First Langston had to find space to carry out his research; then his initial round of grants ran out, and he began to worry about the precarious nature of his funding. So he took the bold step of striking out on his, own. He left the faculty of Stanford University, severed his ties with the Santa Clara Valley Medical Center and, in April, started his own organization, the California Foundation for Parkinson's Disease and Related Disorders, to support his research.

Although it's too soon to tell if the foundation will survive and prosper, Langston sees it as a model for other scientists whose research outgrows the ability of their institutions to support it—a problem he suspects will increasingly crop up in rapidly expanding fields such as neuroscience.

This problem was outlined last year by David H. Cohen, vice president for research at ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies